{"ticker": {"uuid": "5b83d7c6-3fb6-4e8f-ae92-0dda95026387", "symbol": "VNDA", "name": "Vanda Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Vanda Pharma's new motion sickness drug NEREUS\u2122 sponsors No. 47 IndyCar, marking a 47-year treatment milestone", "summary": "Vanda Pharmaceuticals announced that its new FDA-approved motion sickness drug, NEREUS\u2122 (tradipitant), will sponsor the No. 47 IndyCar, highlighting it as the first new prescription treatment for motion-induced vomiting in 47 years. This partnership underscores the drug's signifi", "url": "https://pluang.com/en/news-feed/vanda-pharmaceuticals-nereus-sponsori-tim-indycar-dan-obat-mabuk-perjalanan-baru", "source_name": "Pluang", "published_at": "2026-07-15T21:45:21", "published_display": "15 Jul 2026 21:45", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "47 years since the last new motion-sickness treatment, NEREUS will sponsor IndyCar", "summary": "Vanda Pharmaceuticals announced that its NEREUS\u2122 (tradipitant) medication, the first new prescription treatment for motion-induced vomiting in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series. This partnership with Rahal Letterman Lanigan Racing highlights NEREUS", "url": "https://www.stocktitan.net/news/VNDA/nereustm-powers-forward-sponsors-no-47-indy-car-entry-celebrating-47-orf3y83kosfm.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:45:21", "published_display": "15 Jul 2026 20:45", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IndyCar News: Vanda Pharmaceuticals Sponsor Schumacher for Four Races", "summary": "Vanda Pharmaceuticals, a biopharmaceutical company, announced its sponsorship of Mick Schumacher's No. 47 NTT INDYCAR SERIES entry for four races in 2026. The sponsorship will feature Vanda's NEREUS\u2122 product, an oral neurokinin-1 (NK-1) receptor antagonist for motion-induced vomi", "url": "https://www.autoracing1.com/pl/498423/indycar-news-vanda-pharmaceuticals-sponsor-schumacher-for-four-races/", "source_name": "AutoRacing1.com", "published_at": "2026-07-15T19:45:21", "published_display": "15 Jul 2026 19:45", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Vanda Pharmaceuticals Finally Found Its Game-Changer with Bysanti", "summary": "Vanda Pharmaceuticals (VNDA) recently received FDA approval for Bysanti (milsaperidone) for bipolar I disorder and schizophrenia, expanding its psychiatric drug portfolio. Despite an initial sell-off, this approval, coupled with long patent protection, positions Bysanti as a pote", "url": "https://www.kavout.com/market-lens/has-vanda-pharmaceuticals-finally-found-its-game-changer-with-bysanti", "source_name": "Kavout | AI", "published_at": "2026-07-15T16:45:21", "published_display": "15 Jul 2026 16:45", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxPc21JZUlhSUdqazN3RHpBVnNIaXA5eUZDWlpETVdwRmlFaW1TTmpqQk5fOXpSSEtYdjJjUkFSaVlaZm5WZjA4X1FVeUlwbFdKdVFqOF9sUFFKM0tQRW1aUXZDZTI3by11c0NDcTJKNVBFRlBlVkZESms5ci1FUTMybmlFNVRENzNrSjNyV2FibGRJODZocm1wZUxPVzQ1TndlZFcxZWtPVUV3YnV4TnFmVDhRbVhfMHNkX1hCVnlkTUhfTHhEQlllNlRqbTdKNG11Wi1wbnJhRDZ3NUdEVXZiRE1tLTA0YjQzUTdfbmNtNHE?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-10T20:30:00+00:00", "published_display": "10 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals plans fireside chat at Boston investor summit", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOVHFUaVJucUFrM2RWaDdxbVN3aGR5MVMzTzVEWU1VUTdtWXIzOTJXY1E0aE1NNUpLc19YU3VMLUV0aW5DYXdhU2JZYUdlZ04xay1FZWRhQy1lTGZ6dGJIS0xmWUliak9tRndqU1NoVjhLbWQyUDZlZWRhc0d2U2dLZEY5ZE16U2x3d0l2bjJ3UGI4cHkwemV4alN6QTVYNzYza0YzTFFjbG5ORFE5cTlXenl0Y1JFdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:30:00+00:00", "published_display": "10 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) Short Interest & Short Float | Updated Jul 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE5KOUllUkx2OGRsaW5OSU5ScXVLY0dYREJSZ1cyZG5Tclh6aUlmLXFSUHdJaDRheTZZTFUwU0VJNFBhUG52aGZWLXdWVUE5ajdTMUpRQ1BxZHdlZi15a3dCekVjRkRvcFVCQnBKZVN3?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPSUR0Tk1tUUNDOTdnbS01NEpnS1lrY3RIeUJLeGhMYjc5bkxqMHl2X1ZPMXQtY1NORjluWG9UR0NEdElvQzZmZ0ZqbUpaYlIyUm5qQnVkTmNwOHhkSWYzVE1MdVNlTFA2QjlQcE5nQUNvRlRNMTNnSm84eFNpdHhtWjlhcVQxN0FKYmR6VGlRSzNybG5aZnJwcVFZa1M5VnRwZHBvWl9KQlRuQ0sxQWRTeTFOT2ZrX2lvdDRUQ2tSNkN4QQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-10T00:08:10+00:00", "published_display": "10 Jul 2026 00:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S", "summary": "Vanda Pharmaceuticals announced that its investigational therapy for Charcot-Marie-Tooth Disease Type 2S has received Rare Pediatric Disease Designation from the FDA. This news was delivered via Quantisnow's real-time market data platform. The designation highlights the potential", "url": "https://www.quantisnow.com/insight/vanda-pharmaceuticals-announces-fda-rare-pediatric-disease-designation-for-investigational-6630229", "source_name": "Quantisnow", "published_at": "2026-07-08T10:41:19", "published_display": "08 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Gets FDA Rare Pediatric Disease Designation for CMT2S Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vanda-pharmaceuticals-gets-fda-rare-205451657.html", "source_name": "MT Newswires", "published_at": "2026-07-07T20:54:51+00:00", "published_display": "07 Jul 2026 20:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) Receives FDA Rare Pediatric Disease Designation", "summary": "Vanda Pharmaceuticals (VNDA) has received FDA Rare Pediatric Disease Designation for VCA-894A, an experimental therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S). This designation is a critical step for addressing the rare genetic disorder and could lead to a priori", "url": "https://www.gurufocus.com/news/8948300/vanda-pharmaceuticals-vnda-receives-fda-rare-pediatric-disease-designation", "source_name": "GuruFocus", "published_at": "2026-07-07T21:51:57", "published_display": "07 Jul 2026 21:51", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA gives Vanda pediatric rare-disease designation for CMT2S therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxORUFPUlRpQ3QxQXVWMm95TGszRXlYaF8wdDFEVFNZM1dnNVloWlFaWUg4Y01ONzFKVUFyNUtQX1k3TTctM1BfZ0hoTXJWRjZiaVd1STRCOXFSVWNlRlV0c1RKUjItSldTZ3dabkp2eEJzMzN0Q3dGdVVsdzRndjJONm9oQjh2UHRXUTM1VzZDeThJY2d6OXNVRl9td09sc0haVklPYldSLW9SM1AwQ3E5dDdHUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T20:30:00+00:00", "published_display": "07 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy", "summary": "Vanda Pharmaceuticals (VNDA) saw its stock rise after-hours following the FDA's granting of Rare Pediatric Disease Designation for VCA-894A, its experimental treatment for Charcot-Marie-Tooth disease type 2S. This designation could make Vanda eligible for a priority review vouche", "url": "https://stocktwits.com/news-articles/markets/equity/vnda-stock-gains-after-hours-as-fda-grants-rare-pediatric-disease-designation-for-experimental-therapy/cZmVIyeR7ZA", "source_name": "Stocktwits", "published_at": "2026-07-07T20:22:00", "published_display": "07 Jul 2026 20:22", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals updates investors on business outlook as shares trade in the U.S. market", "summary": "Vanda Pharmaceuticals, a U.S.-based biopharmaceutical company, continues to develop treatments in neurology, psychiatry, and sleep medicine, with its shares trading on the American market. The company focuses on specialty prescription drugs, generating revenue from approved thera", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/vanda-pharmaceuticals-updates-investors-on-business-outlook-as-shares/69716162", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:11:57", "published_display": "07 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VNDA - Vanda Pharmaceuticals Inc Volatility & Greeks", "summary": "This article provides a detailed overview of Vanda Pharmaceuticals Inc. (VNDA), including its latest stock performance, key financial metrics, volatility, and options Greeks. It covers market capitalization, recent earnings data, insider and institutional ownership, and various p", "url": "https://finviz.com/stock?t=VNDA&ty=ocv&ta=1&p=m&ov=chain_strike&s=19", "source_name": "Finviz", "published_at": "2026-07-04T00:41:19", "published_display": "04 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "McDermott Represents Vanda Pharmaceuticals Inc. on Acquisition of PONVORY\u00ae", "summary": "McDermott Will & Emery represented Vanda Pharmaceuticals Inc. in its acquisition of US and Canadian rights to PONVORY\u00ae, a treatment for relapsing forms of multiple sclerosis. The McDermott deal team was led by Kristian Werling with support from numerous other attorneys. This acqu", "url": "https://www.mcdermottlaw.com/it/news/mcdermott-represents-vanda-pharmaceuticals-inc-on-acquisition-of-ponvory-2/", "source_name": "McDermott Will & Schulte", "published_at": "2026-07-03T21:41:34", "published_display": "03 Jul 2026 21:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA)", "summary": "H.C. Wainwright has reiterated a Buy rating for Vanda Pharmaceuticals (VNDA) with a $21 price target, following an update on the company's FDA approval process for HETLIOZ as a jet lag treatment. The FDA has granted Vanda a formal hearing, a rare event, to discuss the drug's appr", "url": "https://www.insidermonkey.com/blog/heres-why-h-c-wainwright-remains-a-buy-on-vanda-pharmaceuticals-vnda-1794174/", "source_name": "Insider Monkey", "published_at": "2026-07-03T13:40:22", "published_display": "03 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index", "summary": "Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) has been removed from the Russell 2000 Defensive Index. This news comes amidst other recent updates for the biopharmaceutical company, including its Q1 2026 earnings call, raising its full-year 2026 revenue guidance, and the U.S. commerc", "url": "https://www.marketscreener.com/news/vanda-pharmaceuticals-inc-nasdaqgm-vnda-dropped-from-russell-2000-defensive-index-ce7f5fdfda8bf521", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:11:57", "published_display": "29 Jun 2026 18:11", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index", "summary": "Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) has been removed from the Russell 2000 Value-Defensive Index. This announcement follows several recent company updates, including its Q1 2026 earnings call, raised revenue guidance, and the U.S. launch of its motion sickness drug Nereus.", "url": "https://www.marketscreener.com/news/vanda-pharmaceuticals-inc-nasdaqgm-vnda-dropped-from-russell-2000-value-defensive-index-ce7f5fdfde80f721", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T07:39:42", "published_display": "29 Jun 2026 07:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Vanda Pharmaceuticals Inc. \u2013 NASDAQ:VNDA", "summary": "This article provides financial information for Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), specifically focusing on its \"Price to book forward\" metric. It appears to be a financial data snippet from TradingView, indicating market closed status and offering an overview of financia", "url": "https://www.tradingview.com/symbols/NASDAQ-VNDA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:40:30", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Vanda Pharmaceuticals Inc. \u2013 FWB:VM4", "summary": "This article provides financial information for Vanda Pharmaceuticals Inc. (FWB:VM4), specifically focusing on its price-to-earnings forward ratio. The content lists the company's stock exchange details, and indicates that the market was closed with no trades recorded at the time", "url": "https://www.tradingview.com/symbols/FWB-VM4/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:11:06", "published_display": "27 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Vanda Pharmaceuticals Inc. \u2013 NASDAQ:VNDA", "summary": "This article provides the \"Price to earnings forward\" value for Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), indicating it's a financial metric available on TradingView. The content primarily focuses on presenting this specific data point for the company, accessible through its fin", "url": "https://www.tradingview.com/symbols/NASDAQ-VNDA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:39:49", "published_display": "27 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Vanda Pharmaceuticals Inc. \u2013 FWB:VM4", "summary": "The article presents the Enterprise Value to EBITDA forward for Vanda Pharmaceuticals Inc. (FWB:VM4) on the Frankfurt Stock Exchange. It provides financial data for this specific metric and indicates that the market was closed with no trades at the time of publication. The conten", "url": "https://www.tradingview.com/symbols/FWB-VM4/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:39:49", "published_display": "27 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Vanda Pharmaceuticals Inc. \u2013 LSX:A0JJT3", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Vanda Pharmaceuticals Inc. (LSX:A0JJT3). It is presented within the context of financial data available on TradingView, specifically under the company's financials section. The content primarily lists an", "url": "https://www.tradingview.com/symbols/LSX-A0JJT3/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:30", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gastroparesis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda", "summary": "This report from DelveInsight highlights the Gastroparesis treatment pipeline for 2026, detailing over 10 therapies from 8+ companies including CinDome Pharma, Evoke Pharma, and Vanda Pharmaceuticals. The report provides an overview of clinical trials, mechanisms of action, and r", "url": "https://www.barchart.com/story/news/17327/gastroparesis-pipeline-2026-therapies-under-investigation-clinical-trials-milestones-and-fda-approvals-by-delveinsight-cindome-pharma-inc-evoke-pharma-vanda-pharma-ironwood-pharma-takeda", "source_name": "Barchart.com", "published_at": "2026-06-26T13:39:49", "published_display": "26 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) Short Interest & Short Float | Updated Jun 2026", "summary": "Vanda Pharmaceuticals (VNDA) saw a 2.61% increase in its short interest, reaching 6.99 million shares sold short as of June 15, 2026, representing 13.01% of its public float. The short interest ratio is currently 7.8 days to cover, suggesting it would take approximately 7.8 days ", "url": "https://www.marketbeat.com/stocks/NASDAQ/VNDA/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-26T06:40:39", "published_display": "26 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VNDA)", "summary": "This article provides an overview of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) stock performance, financials, and analyst forecasts. It covers key metrics like current price, market capitalization, earnings, revenue, and future price predictions from analysts, along with historic", "url": "https://www.tradingview.com/symbols/NASDAQ-VNDA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:30", "published_display": "25 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug", "summary": "Vanda Pharmaceuticals Inc. (VNDA) shares jumped 38% after hours following FDA approval of its Bysanti tablets for treating manic or mixed episodes associated with bipolar I disorder and schizophrenia in adults. Bysanti is expected to be available in Q3 2026 and is also being test", "url": "https://stocktwits.com/news-articles/markets/equity/vnda-stock-rallies-after-hours-as-fda-approves-schizophrenia-bipolar-disorder-drug/cZRNm0xR4xD", "source_name": "Stocktwits", "published_at": "2026-06-25T17:10:29", "published_display": "25 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections", "summary": "Vanda Pharmaceuticals has secured a formal evidentiary public hearing from the FDA to review the refusal of its supplemental new drug application for Hetlioz in treating jet lag disorder. This is a rare move by the FDA, as such hearings for drug approvals have not been granted in", "url": "https://stocktwits.com/news-articles/markets/equity/vanda-looks-to-public-hearing-for-hetlioz-in-jet-lag-disorder-after-multiple-fda-rejections/cZdeA8dRIPx", "source_name": "Stocktwits", "published_at": "2026-06-25T05:10:26", "published_display": "25 Jun 2026 05:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis", "summary": "Vanda Pharmaceuticals Inc (VNDA) currently holds a valuation score of 7.67, placing it 211th out of 389 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -1.48, which is significantly below its recent high and above its recent low. Key valuation metrics", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vnda/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T09:09:37", "published_display": "23 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Inc (VNDA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Vanda Pharmaceuticals Inc (VNDA) currently holds a financial score of 7.53, placing it 110th in the Biotechnology & Medical Research industry. Despite a weak financial status overall, the company shows high operating efficiency, with its latest quarterly revenue increasing by 3.3", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vnda/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T07:09:37", "published_display": "23 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GW Athletics Names Vanda Pharmaceuticals First Official Jersey Patch Partner", "summary": "GW Athletics has announced a landmark partnership with Vanda Pharmaceuticals, making it the first official jersey patch partner in the program's history. This agreement, the largest corporate partnership for GW Athletics, will feature the Vanda logo on all 20 Revolutionaries team", "url": "https://gwsports.com/news/2026/6/22/general-gw-athletics-names-vanda-pharmaceuticals-first-official-jersey-patch-partner", "source_name": "George Washington University Athletics", "published_at": "2026-06-22T17:09:36", "published_display": "22 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU award", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNampRTmhUMllCT2tHUVpSR0VoWGFkY0I3aXNwbGhfbkpmMHExMEFWMHdyV0w0NkNoOXl2NkRybjVmaV9KVVpTcks0c1RZX2llWjVOWVhvdTlwQVdwd1dpSUhHZzI4R1JBYWlMODIyeHp1Sm1OZlUwdE5PcG9GdzJwMnF6Q0FPTmdjNV96ZEFYcEpLaGxmaE5PcmJjT2NhMkU2MktxN1Roemo5R19lc2ZMYWtlYjJLeU1YcjNn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "80,000-share RSU grant to Vanda (VNDA) SVP and General Counsel", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQLTJYcTdCYTBXeFZLTEl4OVg2bWhkZk43ckxXMFJhakktcGszMFhDdDdEOEhOTTdROVVBZFZaVDZNb2NVeHN0TXVWVEVkR2poMXFNaXRIMUhDZVkwd2ZRQ2F0bEo5bThnTGk3bU1VSnFlM1ZrY0N5QkRMWFlvZk9hMWh6VmR2cHozLXp0ZXR2S2thZUpDU3lQZ1d3YzlsN3hMZGk0YjFtdFc1bXFPeV9QTVNtZm9hOUtQRF9J?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxNdUdITWhyNmNmellpeXRycjkzNElXR2VUQm5kTFBuWFVmaHNvbzN1VmhGOE1JYi1UNnFWdDduMURjSmdGMjhyd1l3RkNBYW1VdzFXS0xBcXUzTXRqT1hzOElPSktTNlN1aTBpQ2tDNVFuVEU1dEt1eGFOZS1FU1NzSnlSVjNVUkY0Q1Nza2oxeXEyRURsWktsLXJSaFMxVmc0UUZ5QkthaWt2a0o0bEZsTW9NMmpFcnhmVkUyM3dUU2xaRG0wVHgxclZsMGFITlFrUHdETVVraFhISkN2VUVxYk9DOFVyTVU3Q0NycVRhRktuRHRqZWNBX01oQmpSZzg?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Japan gives special status to Vanda drug for rare, severe skin disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOeW9Bb3FKRDhrWUNzQmQzeWpaU2M5U19CTWw1V2NsdHJmS2FiMUlneTV3UGdXR0RrOTctckF3eHpkaUdvbVBNRmdWLW9IVlJuTjdtWlpoM252ZmxvY2RTNlQ1cFU0ejlxVXNUdWJmUE5NdEhjb2ZWdW9MZGdWM2ZpbS1uY3Mwd2hXaTA3WHFBaHUyMndWUHlkZE5ieDlDS3FNNmVQTTRWQmFGUlR6NjlZX0dCaUhnQk1IWmpfZ3JsQ2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSm01azI2RkNOVFFSTERqRTdkaV84UHNmTDZ2bW94Ny1fc0VCOEkwV21KNFcwYjRwQXB0WHZQd3hpSnFyOVNzRnZFdG1rRy1OV29uYnlFZzhnS1JnakR6Z1lWVHRjbl9ERXVHbkhORkRkdUZhZ2R5Mzdxd2dIYXJMdEt0bm1vVmRqa3dDQ0ZEOE1ISjBYMW52SjUyVTd4Ry1XNERQTFpRN2JEcncx?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vanda Pharmaceuticals (VNDA) Losses Deepen To US$239.5 Million LTM Reinforcing Bearish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPWDVQMWlWM1RNZ3I1Q3hJamJVVWlEaXg0bGlwaFVOUlNKZDQ3cmczMUNRVjNBaDJpdXBnTHI5b2hwcWhHblJuZXM3X0g1S0hQaVlmRnN0QmF2UGo0MVB2ZUpsNEJWS0taRjVkUDRwd3NEdTNyZFNoaDNiRktKZzFPMFA4em5nYUJoT0pfODgwSTlnLUlnVHF1QU1ET3luTUhISnpsbzVzV05qUnZHZFNpOGsydi05R1FtY3BVWF85QQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Vanda Pharmaceuticals misses Q1 2026 forecasts, stock rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPb19ITUliM3dBTk56eVBVTGxZUW9taW9DTFpPMDd1cElzYjdKVTNiT0I5Q0VuU0MxVThSQlotVHlMbDlHOTloNWJOMXpqY3JiX0phVmVyYmk0ZjFlenNxV3hRMU1DQUZGUWxLejR4NE14ZTNLZnpySFExZlRpRElRX2F4RUN5a2hqZENaOGZnQmJ1aGVYZXRjb0JiM0dRdHRwbXdhSVdXZXZzVU9rbWtmY1hDRGVSZ00yU183UmZ1RnA5TS1PeE1PZjVndVpRT3pKdUJVSm5B?oc=5", "source_name": "Investing.com", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcm1kSXBRX0FoMWIxYTlQcGhRdkNJaU5JcG5ZNGthTWw1WTdzd1pCZkc1bF9ldHZHMlFwOHRnNHExejRRQ2FZN2FzeHlMRXlaQnZEWXBjb2pLRzJfdm5rWGZidEZxdnUyTDhmTk5BMFFWQTAzbGM3R2dhQWNmcnF5MzdrYXctNnMxSjNFZ19zN2hiWVM3SDNZS0FjeGszWEg3eDc1cEhUUkJsUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPbUh1bkxMN0VVQ19yazVMcUdJRkZHZ0FjWVJkcGRhVzZ2a1FtelV0T1ZaR1NDbzNsd2JjWFFVMm00Ul9OUDdiYlBqOUc2eWpyLVBoSGZmTTNGSk9FY0d5Z1ZHVURfaGJQRVVzaUFraW8yYXh4d0l4S3k2LThSVEROdlVjbm50NW9uYnNoYlFHY1ZuaDlER3YweFpDT0dJZlUzU1N6Ui1PTVhMVGVPSnpaakdPckxrSU1XSGVOUG9nLWZHNmVoaE5lR19sZEFUNk9yY3d0X2FUWnlxTVhnNTlrQlhEVUV0UjloT3fSAe8BQVVfeXFMT2VhY3owMDBIcW40dTdqTTZ1V1FWM3pqdUx2dVVpSzdWRjdlX0t5bmlpYURZT1IwYTl2RTNtTFUxMTBzN3JzenZCcWFoeFYwN0RPWDZIV3h4cE5QaDV3TmRlN094LXJrYU02LXE2VFVkS09NV2hkZXYzcXJrcFFibjZ1QnhIZG5KVEJ2V1R5dWR6Qm9lMmlIdnMtQWhXcWVhMUhmYXJtSlYtRUM1WlhLd0EwVDlZN205bW1SdXpWNDZINkJtQUVMLTBTVHZmb1NaS0RGUklJcHR2WUQyOTB2eGJTWURWdnppbFJCdDhUQ00?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of Bysanti For Bipolar I Disorder And Schizophrenia", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda stock\u2019s explosive rally may be more hype than substance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPUVgtbnE3VzdnT0pjR3hYZGh3X2FQZ2I5czJ3NDgzUXE3RnZLN0ZSS2N3dGxtR3BGMEczQVB1RS1KLW9Ed19lZXZFOU1mcGc2UUJpTHFtT0JBNXhMWnJRN2hMRGlEcm9kcVFnVmNxT0hVTlVKUmQybFNEOTQ3QWdVVXF5RWY1ZHFDZktvQlQxbTdlN1dNaWM4WVhyWDJHdl83YWlWMEh2Zzl1amR6VXNHVzNnTlVWSHBCU0E?oc=5", "source_name": "TradingView", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPeWYzNlNjeGN0N3VzM2pjeGZ2R3JvdFpsRTNLeEpjb1ZvMUh1Q2NuQnktOWtSTE95MDdIZjlwQ1pPYzVIMmJHQnZmX1NuWjMtd2pMc0dFem00c20xbnp3bUw3a1dnMzg5WGJZUFp5Vk9FUVFjNGFuNmdMZjFUZmJBYmFIeHlJM0NBOC1LUTdDRWw2SEQ4a29oYXlZdGZ3eWtlU3NqOTM3c2lOenplSGJJV2ItZ2gySzNpaUJ0eDhSLWhQdw?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) Stock Falls on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPMm5ZVVNkNFZxcGtpM2JzQkYzc1o4ZE1CMHhTMzdPbHpUMS1iNFlqTFNMR2FiR3dtekpyR1BvM2prYndoYzBsZk9hSEl2aUkzZVA1cktEY1YwSThzTFI5N1lUTkZSOTdnN3lGMlZLTE0yYnBPSWlVUzM3bXVIVGg3Q1hEZFlwNWc4SHBMVXV2bHRWMV92bG90V0RzNHJzdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ\u00ae Supplemental New Drug Application for Jet Lag Disorder", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxPeVJrRzdWRVJZYW82V1hIQ2piNVMxTUZDNXdRLXRab3RsSnFUVFNTUGJnajNWSUhGX20zbnJBNjZmQmIwbFZIbFp6LWxlTHNWNjRGREd6amh1bnotMmVId3hSbWRkdWZYLXdIYmI0dnJMZEl1UXRCck5lc3pjOEp1MHh0Zm9XM3RYRkhKTUNTOUt5UUNJN1pFeU1mLWNEenJzX05tbzhIOVcwdjloejhSMHpUZ0U3RHU2TzdUdk1DeG9iX0RRaTU5QU9NdkVyMVhxUU1aeHhCX1RSa283MmFJWmFWYlJDb2RKM2tPd2lWczlQN0VfZUVrc2MyMnRYQW9namR4dUhDSWxhaFJOOU9wcGFn?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Vanda Pharmaceuticals' motion sickness drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMnM0QjRKNEFIMmNpYnNkSlFxNjlURUJxSjdQT3NDRi02UEJpSjlwZTgtR25JUWdyeEZnQzY4Q0xxenIwN2s5LXhETmhETVRuMl9Damk2dDJDdlB2QkY2dHVmOXJjU3BtcDBfeXY1cU5Nck1GQzdtNnY2NG1EdFRfb2FUSUtMZFVjUkhwUlFmX1ltWTlSNVlRUThKTkVnNTZRc003S0QzOGtta0x6Zm9VQmIwTDJsc3JCd3hNbFEtYWp0anJicDlDRU13?oc=5", "source_name": "Reuters", "published_at": "2025-12-30T08:00:00+00:00", "published_display": "30 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Leads 3 Promising Penny Stocks", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-21T08:00:00+00:00", "published_display": "21 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Vanda Pharma's new motion sickness drug NEREUS\u2122 sponsors No. 47 IndyCar, marking a 47-year treatment milestone", "summary": "Vanda Pharmaceuticals announced that its new FDA-approved motion sickness drug, NEREUS\u2122 (tradipitant), will sponsor the No. 47 IndyCar, highlighting it as the first new prescription treatment for motion-induced vomiting in 47 years. This partnership underscores the drug's signifi", "url": "https://pluang.com/en/news-feed/vanda-pharmaceuticals-nereus-sponsori-tim-indycar-dan-obat-mabuk-perjalanan-baru", "source_name": "Pluang", "published_at": "2026-07-15T21:45:21", "published_display": "15 Jul 2026 21:45", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "47 years since the last new motion-sickness treatment, NEREUS will sponsor IndyCar", "summary": "Vanda Pharmaceuticals announced that its NEREUS\u2122 (tradipitant) medication, the first new prescription treatment for motion-induced vomiting in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series. This partnership with Rahal Letterman Lanigan Racing highlights NEREUS", "url": "https://www.stocktitan.net/news/VNDA/nereustm-powers-forward-sponsors-no-47-indy-car-entry-celebrating-47-orf3y83kosfm.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:45:21", "published_display": "15 Jul 2026 20:45", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IndyCar News: Vanda Pharmaceuticals Sponsor Schumacher for Four Races", "summary": "Vanda Pharmaceuticals, a biopharmaceutical company, announced its sponsorship of Mick Schumacher's No. 47 NTT INDYCAR SERIES entry for four races in 2026. The sponsorship will feature Vanda's NEREUS\u2122 product, an oral neurokinin-1 (NK-1) receptor antagonist for motion-induced vomi", "url": "https://www.autoracing1.com/pl/498423/indycar-news-vanda-pharmaceuticals-sponsor-schumacher-for-four-races/", "source_name": "AutoRacing1.com", "published_at": "2026-07-15T19:45:21", "published_display": "15 Jul 2026 19:45", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Vanda Pharmaceuticals Finally Found Its Game-Changer with Bysanti", "summary": "Vanda Pharmaceuticals (VNDA) recently received FDA approval for Bysanti (milsaperidone) for bipolar I disorder and schizophrenia, expanding its psychiatric drug portfolio. Despite an initial sell-off, this approval, coupled with long patent protection, positions Bysanti as a pote", "url": "https://www.kavout.com/market-lens/has-vanda-pharmaceuticals-finally-found-its-game-changer-with-bysanti", "source_name": "Kavout | AI", "published_at": "2026-07-15T16:45:21", "published_display": "15 Jul 2026 16:45", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxPc21JZUlhSUdqazN3RHpBVnNIaXA5eUZDWlpETVdwRmlFaW1TTmpqQk5fOXpSSEtYdjJjUkFSaVlaZm5WZjA4X1FVeUlwbFdKdVFqOF9sUFFKM0tQRW1aUXZDZTI3by11c0NDcTJKNVBFRlBlVkZESms5ci1FUTMybmlFNVRENzNrSjNyV2FibGRJODZocm1wZUxPVzQ1TndlZFcxZWtPVUV3YnV4TnFmVDhRbVhfMHNkX1hCVnlkTUhfTHhEQlllNlRqbTdKNG11Wi1wbnJhRDZ3NUdEVXZiRE1tLTA0YjQzUTdfbmNtNHE?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-10T20:30:00+00:00", "published_display": "10 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals plans fireside chat at Boston investor summit", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOVHFUaVJucUFrM2RWaDdxbVN3aGR5MVMzTzVEWU1VUTdtWXIzOTJXY1E0aE1NNUpLc19YU3VMLUV0aW5DYXdhU2JZYUdlZ04xay1FZWRhQy1lTGZ6dGJIS0xmWUliak9tRndqU1NoVjhLbWQyUDZlZWRhc0d2U2dLZEY5ZE16U2x3d0l2bjJ3UGI4cHkwemV4alN6QTVYNzYza0YzTFFjbG5ORFE5cTlXenl0Y1JFdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:30:00+00:00", "published_display": "10 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) Short Interest & Short Float | Updated Jul 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE5KOUllUkx2OGRsaW5OSU5ScXVLY0dYREJSZ1cyZG5Tclh6aUlmLXFSUHdJaDRheTZZTFUwU0VJNFBhUG52aGZWLXdWVUE5ajdTMUpRQ1BxZHdlZi15a3dCekVjRkRvcFVCQnBKZVN3?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPSUR0Tk1tUUNDOTdnbS01NEpnS1lrY3RIeUJLeGhMYjc5bkxqMHl2X1ZPMXQtY1NORjluWG9UR0NEdElvQzZmZ0ZqbUpaYlIyUm5qQnVkTmNwOHhkSWYzVE1MdVNlTFA2QjlQcE5nQUNvRlRNMTNnSm84eFNpdHhtWjlhcVQxN0FKYmR6VGlRSzNybG5aZnJwcVFZa1M5VnRwZHBvWl9KQlRuQ0sxQWRTeTFOT2ZrX2lvdDRUQ2tSNkN4QQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-10T00:08:10+00:00", "published_display": "10 Jul 2026 00:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S", "summary": "Vanda Pharmaceuticals announced that its investigational therapy for Charcot-Marie-Tooth Disease Type 2S has received Rare Pediatric Disease Designation from the FDA. This news was delivered via Quantisnow's real-time market data platform. The designation highlights the potential", "url": "https://www.quantisnow.com/insight/vanda-pharmaceuticals-announces-fda-rare-pediatric-disease-designation-for-investigational-6630229", "source_name": "Quantisnow", "published_at": "2026-07-08T10:41:19", "published_display": "08 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Gets FDA Rare Pediatric Disease Designation for CMT2S Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vanda-pharmaceuticals-gets-fda-rare-205451657.html", "source_name": "MT Newswires", "published_at": "2026-07-07T20:54:51+00:00", "published_display": "07 Jul 2026 20:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) Receives FDA Rare Pediatric Disease Designation", "summary": "Vanda Pharmaceuticals (VNDA) has received FDA Rare Pediatric Disease Designation for VCA-894A, an experimental therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S). This designation is a critical step for addressing the rare genetic disorder and could lead to a priori", "url": "https://www.gurufocus.com/news/8948300/vanda-pharmaceuticals-vnda-receives-fda-rare-pediatric-disease-designation", "source_name": "GuruFocus", "published_at": "2026-07-07T21:51:57", "published_display": "07 Jul 2026 21:51", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA gives Vanda pediatric rare-disease designation for CMT2S therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxORUFPUlRpQ3QxQXVWMm95TGszRXlYaF8wdDFEVFNZM1dnNVloWlFaWUg4Y01ONzFKVUFyNUtQX1k3TTctM1BfZ0hoTXJWRjZiaVd1STRCOXFSVWNlRlV0c1RKUjItSldTZ3dabkp2eEJzMzN0Q3dGdVVsdzRndjJONm9oQjh2UHRXUTM1VzZDeThJY2d6OXNVRl9td09sc0haVklPYldSLW9SM1AwQ3E5dDdHUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T20:30:00+00:00", "published_display": "07 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy", "summary": "Vanda Pharmaceuticals (VNDA) saw its stock rise after-hours following the FDA's granting of Rare Pediatric Disease Designation for VCA-894A, its experimental treatment for Charcot-Marie-Tooth disease type 2S. This designation could make Vanda eligible for a priority review vouche", "url": "https://stocktwits.com/news-articles/markets/equity/vnda-stock-gains-after-hours-as-fda-grants-rare-pediatric-disease-designation-for-experimental-therapy/cZmVIyeR7ZA", "source_name": "Stocktwits", "published_at": "2026-07-07T20:22:00", "published_display": "07 Jul 2026 20:22", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals updates investors on business outlook as shares trade in the U.S. market", "summary": "Vanda Pharmaceuticals, a U.S.-based biopharmaceutical company, continues to develop treatments in neurology, psychiatry, and sleep medicine, with its shares trading on the American market. The company focuses on specialty prescription drugs, generating revenue from approved thera", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/vanda-pharmaceuticals-updates-investors-on-business-outlook-as-shares/69716162", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:11:57", "published_display": "07 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VNDA - Vanda Pharmaceuticals Inc Volatility & Greeks", "summary": "This article provides a detailed overview of Vanda Pharmaceuticals Inc. (VNDA), including its latest stock performance, key financial metrics, volatility, and options Greeks. It covers market capitalization, recent earnings data, insider and institutional ownership, and various p", "url": "https://finviz.com/stock?t=VNDA&ty=ocv&ta=1&p=m&ov=chain_strike&s=19", "source_name": "Finviz", "published_at": "2026-07-04T00:41:19", "published_display": "04 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "McDermott Represents Vanda Pharmaceuticals Inc. on Acquisition of PONVORY\u00ae", "summary": "McDermott Will & Emery represented Vanda Pharmaceuticals Inc. in its acquisition of US and Canadian rights to PONVORY\u00ae, a treatment for relapsing forms of multiple sclerosis. The McDermott deal team was led by Kristian Werling with support from numerous other attorneys. This acqu", "url": "https://www.mcdermottlaw.com/it/news/mcdermott-represents-vanda-pharmaceuticals-inc-on-acquisition-of-ponvory-2/", "source_name": "McDermott Will & Schulte", "published_at": "2026-07-03T21:41:34", "published_display": "03 Jul 2026 21:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA)", "summary": "H.C. Wainwright has reiterated a Buy rating for Vanda Pharmaceuticals (VNDA) with a $21 price target, following an update on the company's FDA approval process for HETLIOZ as a jet lag treatment. The FDA has granted Vanda a formal hearing, a rare event, to discuss the drug's appr", "url": "https://www.insidermonkey.com/blog/heres-why-h-c-wainwright-remains-a-buy-on-vanda-pharmaceuticals-vnda-1794174/", "source_name": "Insider Monkey", "published_at": "2026-07-03T13:40:22", "published_display": "03 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index", "summary": "Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) has been removed from the Russell 2000 Defensive Index. This news comes amidst other recent updates for the biopharmaceutical company, including its Q1 2026 earnings call, raising its full-year 2026 revenue guidance, and the U.S. commerc", "url": "https://www.marketscreener.com/news/vanda-pharmaceuticals-inc-nasdaqgm-vnda-dropped-from-russell-2000-defensive-index-ce7f5fdfda8bf521", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:11:57", "published_display": "29 Jun 2026 18:11", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index", "summary": "Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) has been removed from the Russell 2000 Value-Defensive Index. This announcement follows several recent company updates, including its Q1 2026 earnings call, raised revenue guidance, and the U.S. launch of its motion sickness drug Nereus.", "url": "https://www.marketscreener.com/news/vanda-pharmaceuticals-inc-nasdaqgm-vnda-dropped-from-russell-2000-value-defensive-index-ce7f5fdfde80f721", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T07:39:42", "published_display": "29 Jun 2026 07:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Vanda Pharmaceuticals Inc. \u2013 NASDAQ:VNDA", "summary": "This article provides financial information for Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), specifically focusing on its \"Price to book forward\" metric. It appears to be a financial data snippet from TradingView, indicating market closed status and offering an overview of financia", "url": "https://www.tradingview.com/symbols/NASDAQ-VNDA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:40:30", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Vanda Pharmaceuticals Inc. \u2013 FWB:VM4", "summary": "This article provides financial information for Vanda Pharmaceuticals Inc. (FWB:VM4), specifically focusing on its price-to-earnings forward ratio. The content lists the company's stock exchange details, and indicates that the market was closed with no trades recorded at the time", "url": "https://www.tradingview.com/symbols/FWB-VM4/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:11:06", "published_display": "27 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Vanda Pharmaceuticals Inc. \u2013 NASDAQ:VNDA", "summary": "This article provides the \"Price to earnings forward\" value for Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), indicating it's a financial metric available on TradingView. The content primarily focuses on presenting this specific data point for the company, accessible through its fin", "url": "https://www.tradingview.com/symbols/NASDAQ-VNDA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:39:49", "published_display": "27 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Vanda Pharmaceuticals Inc. \u2013 FWB:VM4", "summary": "The article presents the Enterprise Value to EBITDA forward for Vanda Pharmaceuticals Inc. (FWB:VM4) on the Frankfurt Stock Exchange. It provides financial data for this specific metric and indicates that the market was closed with no trades at the time of publication. The conten", "url": "https://www.tradingview.com/symbols/FWB-VM4/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:39:49", "published_display": "27 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Vanda Pharmaceuticals Inc. \u2013 LSX:A0JJT3", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Vanda Pharmaceuticals Inc. (LSX:A0JJT3). It is presented within the context of financial data available on TradingView, specifically under the company's financials section. The content primarily lists an", "url": "https://www.tradingview.com/symbols/LSX-A0JJT3/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:30", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gastroparesis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda", "summary": "This report from DelveInsight highlights the Gastroparesis treatment pipeline for 2026, detailing over 10 therapies from 8+ companies including CinDome Pharma, Evoke Pharma, and Vanda Pharmaceuticals. The report provides an overview of clinical trials, mechanisms of action, and r", "url": "https://www.barchart.com/story/news/17327/gastroparesis-pipeline-2026-therapies-under-investigation-clinical-trials-milestones-and-fda-approvals-by-delveinsight-cindome-pharma-inc-evoke-pharma-vanda-pharma-ironwood-pharma-takeda", "source_name": "Barchart.com", "published_at": "2026-06-26T13:39:49", "published_display": "26 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) Short Interest & Short Float | Updated Jun 2026", "summary": "Vanda Pharmaceuticals (VNDA) saw a 2.61% increase in its short interest, reaching 6.99 million shares sold short as of June 15, 2026, representing 13.01% of its public float. The short interest ratio is currently 7.8 days to cover, suggesting it would take approximately 7.8 days ", "url": "https://www.marketbeat.com/stocks/NASDAQ/VNDA/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-26T06:40:39", "published_display": "26 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VNDA)", "summary": "This article provides an overview of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) stock performance, financials, and analyst forecasts. It covers key metrics like current price, market capitalization, earnings, revenue, and future price predictions from analysts, along with historic", "url": "https://www.tradingview.com/symbols/NASDAQ-VNDA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:30", "published_display": "25 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug", "summary": "Vanda Pharmaceuticals Inc. (VNDA) shares jumped 38% after hours following FDA approval of its Bysanti tablets for treating manic or mixed episodes associated with bipolar I disorder and schizophrenia in adults. Bysanti is expected to be available in Q3 2026 and is also being test", "url": "https://stocktwits.com/news-articles/markets/equity/vnda-stock-rallies-after-hours-as-fda-approves-schizophrenia-bipolar-disorder-drug/cZRNm0xR4xD", "source_name": "Stocktwits", "published_at": "2026-06-25T17:10:29", "published_display": "25 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections", "summary": "Vanda Pharmaceuticals has secured a formal evidentiary public hearing from the FDA to review the refusal of its supplemental new drug application for Hetlioz in treating jet lag disorder. This is a rare move by the FDA, as such hearings for drug approvals have not been granted in", "url": "https://stocktwits.com/news-articles/markets/equity/vanda-looks-to-public-hearing-for-hetlioz-in-jet-lag-disorder-after-multiple-fda-rejections/cZdeA8dRIPx", "source_name": "Stocktwits", "published_at": "2026-06-25T05:10:26", "published_display": "25 Jun 2026 05:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis", "summary": "Vanda Pharmaceuticals Inc (VNDA) currently holds a valuation score of 7.67, placing it 211th out of 389 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -1.48, which is significantly below its recent high and above its recent low. Key valuation metrics", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vnda/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T09:09:37", "published_display": "23 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Inc (VNDA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Vanda Pharmaceuticals Inc (VNDA) currently holds a financial score of 7.53, placing it 110th in the Biotechnology & Medical Research industry. Despite a weak financial status overall, the company shows high operating efficiency, with its latest quarterly revenue increasing by 3.3", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vnda/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T07:09:37", "published_display": "23 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GW Athletics Names Vanda Pharmaceuticals First Official Jersey Patch Partner", "summary": "GW Athletics has announced a landmark partnership with Vanda Pharmaceuticals, making it the first official jersey patch partner in the program's history. This agreement, the largest corporate partnership for GW Athletics, will feature the Vanda logo on all 20 Revolutionaries team", "url": "https://gwsports.com/news/2026/6/22/general-gw-athletics-names-vanda-pharmaceuticals-first-official-jersey-patch-partner", "source_name": "George Washington University Athletics", "published_at": "2026-06-22T17:09:36", "published_display": "22 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU award", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNampRTmhUMllCT2tHUVpSR0VoWGFkY0I3aXNwbGhfbkpmMHExMEFWMHdyV0w0NkNoOXl2NkRybjVmaV9KVVpTcks0c1RZX2llWjVOWVhvdTlwQVdwd1dpSUhHZzI4R1JBYWlMODIyeHp1Sm1OZlUwdE5PcG9GdzJwMnF6Q0FPTmdjNV96ZEFYcEpLaGxmaE5PcmJjT2NhMkU2MktxN1Roemo5R19lc2ZMYWtlYjJLeU1YcjNn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "80,000-share RSU grant to Vanda (VNDA) SVP and General Counsel", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQLTJYcTdCYTBXeFZLTEl4OVg2bWhkZk43ckxXMFJhakktcGszMFhDdDdEOEhOTTdROVVBZFZaVDZNb2NVeHN0TXVWVEVkR2poMXFNaXRIMUhDZVkwd2ZRQ2F0bEo5bThnTGk3bU1VSnFlM1ZrY0N5QkRMWFlvZk9hMWh6VmR2cHozLXp0ZXR2S2thZUpDU3lQZ1d3YzlsN3hMZGk0YjFtdFc1bXFPeV9QTVNtZm9hOUtQRF9J?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxNdUdITWhyNmNmellpeXRycjkzNElXR2VUQm5kTFBuWFVmaHNvbzN1VmhGOE1JYi1UNnFWdDduMURjSmdGMjhyd1l3RkNBYW1VdzFXS0xBcXUzTXRqT1hzOElPSktTNlN1aTBpQ2tDNVFuVEU1dEt1eGFOZS1FU1NzSnlSVjNVUkY0Q1Nza2oxeXEyRURsWktsLXJSaFMxVmc0UUZ5QkthaWt2a0o0bEZsTW9NMmpFcnhmVkUyM3dUU2xaRG0wVHgxclZsMGFITlFrUHdETVVraFhISkN2VUVxYk9DOFVyTVU3Q0NycVRhRktuRHRqZWNBX01oQmpSZzg?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Japan gives special status to Vanda drug for rare, severe skin disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOeW9Bb3FKRDhrWUNzQmQzeWpaU2M5U19CTWw1V2NsdHJmS2FiMUlneTV3UGdXR0RrOTctckF3eHpkaUdvbVBNRmdWLW9IVlJuTjdtWlpoM252ZmxvY2RTNlQ1cFU0ejlxVXNUdWJmUE5NdEhjb2ZWdW9MZGdWM2ZpbS1uY3Mwd2hXaTA3WHFBaHUyMndWUHlkZE5ieDlDS3FNNmVQTTRWQmFGUlR6NjlZX0dCaUhnQk1IWmpfZ3JsQ2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSm01azI2RkNOVFFSTERqRTdkaV84UHNmTDZ2bW94Ny1fc0VCOEkwV21KNFcwYjRwQXB0WHZQd3hpSnFyOVNzRnZFdG1rRy1OV29uYnlFZzhnS1JnakR6Z1lWVHRjbl9ERXVHbkhORkRkdUZhZ2R5Mzdxd2dIYXJMdEt0bm1vVmRqa3dDQ0ZEOE1ISjBYMW52SjUyVTd4Ry1XNERQTFpRN2JEcncx?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) Losses Deepen To US$239.5 Million LTM Reinforcing Bearish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPWDVQMWlWM1RNZ3I1Q3hJamJVVWlEaXg0bGlwaFVOUlNKZDQ3cmczMUNRVjNBaDJpdXBnTHI5b2hwcWhHblJuZXM3X0g1S0hQaVlmRnN0QmF2UGo0MVB2ZUpsNEJWS0taRjVkUDRwd3NEdTNyZFNoaDNiRktKZzFPMFA4em5nYUJoT0pfODgwSTlnLUlnVHF1QU1ET3luTUhISnpsbzVzV05qUnZHZFNpOGsydi05R1FtY3BVWF85QQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Vanda Pharmaceuticals misses Q1 2026 forecasts, stock rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPb19ITUliM3dBTk56eVBVTGxZUW9taW9DTFpPMDd1cElzYjdKVTNiT0I5Q0VuU0MxVThSQlotVHlMbDlHOTloNWJOMXpqY3JiX0phVmVyYmk0ZjFlenNxV3hRMU1DQUZGUWxLejR4NE14ZTNLZnpySFExZlRpRElRX2F4RUN5a2hqZENaOGZnQmJ1aGVYZXRjb0JiM0dRdHRwbXdhSVdXZXZzVU9rbWtmY1hDRGVSZ00yU183UmZ1RnA5TS1PeE1PZjVndVpRT3pKdUJVSm5B?oc=5", "source_name": "Investing.com", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcm1kSXBRX0FoMWIxYTlQcGhRdkNJaU5JcG5ZNGthTWw1WTdzd1pCZkc1bF9ldHZHMlFwOHRnNHExejRRQ2FZN2FzeHlMRXlaQnZEWXBjb2pLRzJfdm5rWGZidEZxdnUyTDhmTk5BMFFWQTAzbGM3R2dhQWNmcnF5MzdrYXctNnMxSjNFZ19zN2hiWVM3SDNZS0FjeGszWEg3eDc1cEhUUkJsUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of Bysanti For Bipolar I Disorder And Schizophrenia", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda stock\u2019s explosive rally may be more hype than substance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPUVgtbnE3VzdnT0pjR3hYZGh3X2FQZ2I5czJ3NDgzUXE3RnZLN0ZSS2N3dGxtR3BGMEczQVB1RS1KLW9Ed19lZXZFOU1mcGc2UUJpTHFtT0JBNXhMWnJRN2hMRGlEcm9kcVFnVmNxT0hVTlVKUmQybFNEOTQ3QWdVVXF5RWY1ZHFDZktvQlQxbTdlN1dNaWM4WVhyWDJHdl83YWlWMEh2Zzl1amR6VXNHVzNnTlVWSHBCU0E?oc=5", "source_name": "TradingView", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPeWYzNlNjeGN0N3VzM2pjeGZ2R3JvdFpsRTNLeEpjb1ZvMUh1Q2NuQnktOWtSTE95MDdIZjlwQ1pPYzVIMmJHQnZmX1NuWjMtd2pMc0dFem00c20xbnp3bUw3a1dnMzg5WGJZUFp5Vk9FUVFjNGFuNmdMZjFUZmJBYmFIeHlJM0NBOC1LUTdDRWw2SEQ4a29oYXlZdGZ3eWtlU3NqOTM3c2lOenplSGJJV2ItZ2gySzNpaUJ0eDhSLWhQdw?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals (VNDA) Stock Falls on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPMm5ZVVNkNFZxcGtpM2JzQkYzc1o4ZE1CMHhTMzdPbHpUMS1iNFlqTFNMR2FiR3dtekpyR1BvM2prYndoYzBsZk9hSEl2aUkzZVA1cktEY1YwSThzTFI5N1lUTkZSOTdnN3lGMlZLTE0yYnBPSWlVUzM3bXVIVGg3Q1hEZFlwNWc4SHBMVXV2bHRWMV92bG90V0RzNHJzdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ\u00ae Supplemental New Drug Application for Jet Lag Disorder", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxPeVJrRzdWRVJZYW82V1hIQ2piNVMxTUZDNXdRLXRab3RsSnFUVFNTUGJnajNWSUhGX20zbnJBNjZmQmIwbFZIbFp6LWxlTHNWNjRGREd6amh1bnotMmVId3hSbWRkdWZYLXdIYmI0dnJMZEl1UXRCck5lc3pjOEp1MHh0Zm9XM3RYRkhKTUNTOUt5UUNJN1pFeU1mLWNEenJzX05tbzhIOVcwdjloejhSMHpUZ0U3RHU2TzdUdk1DeG9iX0RRaTU5QU9NdkVyMVhxUU1aeHhCX1RSa283MmFJWmFWYlJDb2RKM2tPd2lWczlQN0VfZUVrc2MyMnRYQW9namR4dUhDSWxhaFJOOU9wcGFn?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Vanda Pharmaceuticals' motion sickness drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMnM0QjRKNEFIMmNpYnNkSlFxNjlURUJxSjdQT3NDRi02UEJpSjlwZTgtR25JUWdyeEZnQzY4Q0xxenIwN2s5LXhETmhETVRuMl9Damk2dDJDdlB2QkY2dHVmOXJjU3BtcDBfeXY1cU5Nck1GQzdtNnY2NG1EdFRfb2FUSUtMZFVjUkhwUlFmX1ltWTlSNVlRUThKTkVnNTZRc003S0QzOGtta0x6Zm9VQmIwTDJsc3JCd3hNbFEtYWp0anJicDlDRU13?oc=5", "source_name": "Reuters", "published_at": "2025-12-30T08:00:00+00:00", "published_display": "30 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanda Pharmaceuticals Leads 3 Promising Penny Stocks", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-21T08:00:00+00:00", "published_display": "21 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 57, "sentiment_summary": {"positive": 14, "negative": 9, "neutral": 34, "score": 54, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 14.65, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 10.45, "count": 21}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 6.24, "latest_week": "2026-07-10", "one_week_move": 0.5, "four_week_move": 6.3, "twelve_week_move": -14.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.110877, "market_dynamics_buy_signal": false, "relative_strength": -11.559986, "fair_value_gap": 20.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "positive", "expectation_probability": 55.2266, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.5% over one week, +6.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 52, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "simplywall.st", "count": 6}, {"label": "Stocktwits", "count": 5}, {"label": "PR Newswire", "count": 4}, {"label": "MarketBeat", "count": 2}, {"label": "www.marketscreener.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 21}, {"label": "Regulatory and legal", "count": 5}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.5% over one week, +6.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Vanda Pharma's new motion sickness drug NEREUS\u2122 sponsors No. 47 IndyCar, marking a 47-year treatment milestone"}], "updated_at": "2026-07-16T03:02:00.480766+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}